ClinicalTrials.gg
CompletedNCT03586427AGN-241751Updated Apr 27, 2026Results posted

Zelquistinel in the Treatment of Major Depressive Disorder

A Phase 2 interventional study of AGN-241751 and Placebo in Depressive Disorder, Major, sponsored by Syndeio Biosciences, Inc. Completed at 25 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Syndeio Biosciences, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
288th of 1,323
251 · median 70
Started
2018
with 49 others
Phase 2
271 of 1,500
45 open now
Registered
944th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 288th largest by enrollment of the 1,323 interventional ones that give a count, is one of 50 that started in 2018, is one of 271 in phase 2, and was the 944th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from the participant has been obtained prior to any study -related procedures (as described in Appendix 3).
  • Male or female participants must be 18 to 65 years of age, inclusive, at the time of signing the informed consent.
  • Meet , 5th Edition (DSM-5) criteria for MDD (based on confirmation from the modified Structured Clinical Interview for DSM disorders [SCID]), with a current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1.
  • Have a minimum score of 26 on the rater-administered Montgomery-Asberg depression rating scale (MADRS) and a minimum score of 24 on the computer-administered MADRS at both Visit 1 (Screening) and Visit 2 (Baseline).
  • Have a difference of no greater than 7 points between the rater-administered MADRS and computer-administered MADRS at both Visit 1 (Screening) and Visit 2 (Baseline).
  • Have a clinical global impression-severity (CGI-S) score ≥ 4 at both Visit 1 (Screening) and Visit 2 (Baseline).
  • Have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test if a woman of (WOCBP).
  • Female participants willing to minimize the risk of becoming pregnancy for the duration of the clinical study and follow-up period. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
  • not a WOCBP OR
  • A WOCBP who agrees to follow the guidance in Appendix 5 of protocol during the treatment period and for at least 5 terminal half-lives after the last dose of study treatment.
  • Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. A male participant must agree to use contraception as detailed in Appendix 5 of this protocol during the treatment period and for at least 5 terminal half-lives after the last dose of study treatment and refrain from donating sperm during this period.
  • Able, as assessed by the investigator, and willing to follow study instructions and likely to complete all required study visits.
  • Normal physical-examination findings, clinical-laboratory test results, and (ECG) results from Visit 1 (Screening) or abnormal results that are determined to be not by the investigator.
  • (BMI) within the range 18 and 40 kg/m\^2 (inclusive).
  • Eligibility confirmed through a formal adjudication process (see Section 9 Diagnostic Assessments).

Exclusion criteria

Exclusion Criteria:

Psychiatric and Treatment-Related Criteria

  • -based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1. Comorbid generalized anxiety disorder, social anxiety disorder, or specific phobias are acceptable provided they play a secondary role in the balance of symptoms and are not the primary driver of treatment decisions.
  • Lifetime history of meeting DSM-5 criteria for:
  • Schizophrenia spectrum or other psychotic disorder
  • Bipolar or related disorder
  • Major neurocognitive disorder
  • Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
  • Dissociative disorder
  • Posttraumatic stress disorder
  • MDD with psychotic features
  • History of meeting DSM-5 criteria for alcohol or substance use disorder (other than nicotine or caffeine) within the 6 months before Visit 1.
  • DSM-5-based diagnosis of any personality disorder of sufficient severity to interfere with participation in this study in the opinion of the investigator.
  • History (based on participant report and/or medical records, and investigator judgment) of:
  • Inadequate response to electroconvulsive therapy (ECT), a monoamine oxidase inhibitor, ketamine, or adjunctive treatment with an antipsychotic
  • Treatment with clozapine or any depot antipsychotic
  • ECT, vagus nerve stimulation, transcranial magnetic stimulation, or any experimental central nervous system treatment during the current episode or in the 6 months before Visit 1 (whichever is longer)
  • Tardive dyskinesia, serotonin syndrome, or neuroleptic malignant syndrome
  • Having received:
  • Anticonvulsant/mood stabilizer, within 1 year prior to Visit 1
  • Antipsychotic in the current episode, with the exception of quetiapine given for insomnia ≤ 50 mg/day provided it can be safely discontinued prior to Visit 2
  • Combination therapy of 2 or more antidepressant therapies (ADTs) in the current episode if given for depression at adequate dose and duration
  • ADT augmentation agent in the current episode
  • Lifetime history of nonresponse to ≥ 2 antidepressants after adequate trials (adequate treatment is defined as at least 6 weeks at an adequate dose(s) based on approved package insert recommendations) or a non-response to an antidepressant after adequate treatment for the current major depressive episode.
  • Positive result at Visit 1 from the urine drug screen (UDS) test for any prohibited medication. Exception: participants with a positive UDS at Visit 1 for opiates, cannabinoids, or episodic use of benzodiazepines may be allowed in the study provided:
  • The drug was used for a legitimate medical purpose;
  • The drug can be discontinued prior to participation in the study (except for episodic use of benzodiazepines which may be continued); and
  • A repeat UDS is negative for these substances prior to enrollment (except for episodic use of benzodiazepines which may be continued)
  • Suicide risk, as determined by meeting any of the following criteria:
  • A suicide attempt within the past year
  • Significant risk, as judged by the investigator, based on the psychiatric interview or information collected in the C-SSRS at Visit 1 (Screening) or Visit 2 (Baseline)
  • MADRS Item 10 score ≥ 5 at Visit 1 (Screening) or Visit 2 (Baseline) on the MADRS
  • At imminent risk of injuring self or others or causing significant damage to property, as judged by the investigator.
  • Requiring concomitant treatment with any of the prohibited medications, supplements, or herbal products listed in Appendix 6 of protocol, including any psychotropic drug or any drug with psychotropic activity, except as described in Section 7.7.2. of protocol.
  • Prior participation in any study of AGN-241751.
  • Initiation or termination of psychotherapy for depression within the 3 months preceding Visit 1, or plans to initiate, terminate, or change such therapy during the course of the study. (Support meetings or counselling [eg, marital counselling] are allowed provided they are no more frequent than weekly and do not have treatment of depression as their objective).
  • Ongoing treatment with phototherapy, or termination of phototherapy within 1 month of Visit 1.
  • Known allergy or sensitivity to the study medication or its components.

Other Medical Criteria

  • \< 18 kg/m\^2 or > 40 kg/m\^2 at screening.
  • Females who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
  • and male partners of WOCBP, not using a reliable means of (Appendix 5 of protocol).
  • Participant has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study.
  • Any cardiovascular disease that is , unstable, or decompensated.
  • Heart rate (supine) of ≤ 45 beats per minute (bpm) or ≥ 120 bpm, or any heart rate that is clinically symptomatic at Visit 1 or Visit 2 based upon vital signs.
  • Any systolic and/or diastolic blood pressure (BP) that is symptomatic or clinically significant in the opinion of the investigator.
  • History of congenital prolongation or QTc prolongation (screening with QTcF ≥ 450 msec for men and QTcF ≥ 470 msec for women).
  • Hypothyroidism or hyperthyroidism, unless stabilized on appropriate pharmacotherapy with no change in dosage for at least 1 month before Visit 1.
  • History of seizure disorder, stroke, significant head injury, tumor of the central nervous system, or any other condition that predisposes to seizure.
  • Known (HIV) infection.
  • Positive antibody on screening, with the exception of participants for whom the reflex hepatitis C virus ribonucleic acid (HCV RNA) test is negative.
  • Positive test for surface antigen and/or hepatitis B core antibody immunoglobulin M.
  • Screening liver enzyme test ( [AST] and/or alanine aminotransferase [ALT]) results > 2 times the (ULN).

Other Criteria

  • Current enrollment in an investigational drug or device study or participation in such a study within 6 months of entry into this study.
  • Employee, or immediate relative of an employee, of the sponsor, any of its affiliates or partners, or the study center.
  • Inability to speak, read, and understand the English language sufficiently to understand the nature of the study, to provide written , or to allow the completion of all study assessments.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    AGN-241751 Dose 1

    AGN-241751 Dose 1 administered as 1 tablet taken orally every day

    Drug: AGN-241751

  • Experimental
    AGN-241751 Dose 2

    AGN-241751 Dose 2 administered as 1 tablet taken orally every day

    Drug: AGN-241751

  • Experimental
    AGN-241751 Dose 3

    AGN-241751 Dose 3 administered as 1 tablet taken orally every day

    Drug: AGN-241751

  • Experimental
    AGN-241751 Dose 4

    AGN-241751 Dose 4 administered as 1 tablet taken orally every day

    Drug: AGN-241751

  • Placebo comparator
    Placebo

    Placebo administered as 1 tablet taken orally every day

    Drug: Placebo

Interventions

  • AGN-241751 administered orally as a single tablet

  • DrugPlacebo

    Placebo administered orally as a single tablet

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

    Time frame: Baseline to Day 1

Secondary outcomes

  1. Change From Baseline in MADRS Total Score at Week 3

    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

    Time frame: Baseline to Week 3

07

Results

Posted Aug 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneAGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4Placebo
Started4850525051
Completed4846464646
Not completed04645
Withdrew: Lost to follow-up03133
Withdrew: Withdrawal by subject01211
Withdrew: Adverse event00100
Withdrew: Protocol violation00101
Withdrew: Noncompliance with study drug00100

Outcome measures

PrimaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

Time frame:
Baseline to Day 1
Reported as:
Least squares mean · score on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scaleAGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4Placebo
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-8.6 ± 1.21-8.0 ± 1.19-9.5 ± 1.18-10.6 ± 1.18-7.7 ± 1.18
Statistical analysis
  • AGN-241751 Dose 1 vs AGN-241751 Dose 2 vs AGN-241751 Dose 3 vs AGN-241751 Dose 4 vs Placebo · Mixed Models Analysis · p = >0.05 (Comparison of each dose level change from baseline to placebo baseline yielded P values \>0.05)
SecondaryChange From Baseline in MADRS Total Score at Week 3

The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

Time frame:
Baseline to Week 3
Reported as:
Least squares mean · score on a scale
Change From Baseline in MADRS Total Score at Week 3
score on a scaleAGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4Placebo
Change From Baseline in MADRS Total Score at Week 3-11.5 ± 1.56-12.5 ± 1.54-14.1 ± 1.55-13.5 ± 1.54-13.6 ± 1.54

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AGN-241751 Dose 10/48 (0%)0/48 (0%)17/48 (35.4%)
AGN-241751 Dose 20/50 (0%)0/50 (0%)18/50 (36%)
AGN-241751 Dose 30/52 (0%)0/52 (0%)12/52 (23.1%)
AGN-241751 Dose 40/50 (0%)0/50 (0%)19/50 (38%)
Placebo0/51 (0%)0/51 (0%)16/51 (31.4%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4Placebo
InsomniaNervous system disorders0/485/500/521/501/51
HeadacheNervous system disorders3/483/503/522/504/51
DizzinessNervous system disorders2/480/503/523/502/51
NauseaGastrointestinal disorders1/483/502/521/502/51
Dry MouthGastrointestinal disorders0/481/500/523/501/51
AnxietyPsychiatric disorders0/481/503/521/500/51
SomnolenceNervous system disorders2/481/500/521/502/51
SedationNervous system disorders2/480/500/521/502/51
Upper Respiratory Tract InfectionInfections and infestations2/481/501/522/501/51
DiarrheaGastrointestinal disorders2/480/500/521/500/51

Baseline characteristics

Age, Continuous
Age, Continuous(years)AGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4PlaceboTotal
Mean41.8 ± 14.0241.8 ± 13.5342.2 ± 14.2342.9 ± 13.4840.0 ± 14.4941.7 ± 13.88
Sex: Female, Male
Sex: Female, Male(Participants)AGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4PlaceboTotal
Female3315162030114
Male1535363021137
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4PlaceboTotal
American Indian or Alaska Native000011
Asian311218
Native Hawaiian or Other Pacific Islander100001
Black or African American182422152099
White2424283227135
More than one race111025
Unknown or Not Reported100102
Region of Enrollment
Region of Enrollment(participants)AGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4PlaceboTotal
United States4850525051251
Current antidepressant usage
Current antidepressant usage(Participants)AGN-241751 Dose 1AGN-241751 Dose 2AGN-241751 Dose 3AGN-241751 Dose 4PlaceboTotal
Count of participants71313131157
08

Study locations

25 sites
  • Health Initiatives Research PLLC
    Fayetteville, Arkansas 72703, United States
  • Synexus US - Cerritos
    Cerritos, California 90703, United States
  • Wake Research - Pharmacology Research Institute
    Encino, California 91316, United States
  • Wake Research - Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Pacific Research Partners, LLC
    Oakland, California 94607, United States
  • North County Clinical Research, Inc.
    Oceanside, California 92054, United States
  • Collaborative Neuroscience Network
    Torrance, California 90502, United States
  • Elite Clinical Trials, Inc.
    Wildomar, California 92595, United States
  • Synexus US - Atlanta
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Pillar Clinical Research
    Lincolnwood, Illinois 60712, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Neurobehavioral Research, Inc
    Cedarhurst, New York 11516, United States
  • Synexus US - Queens
    Jamaica, New York 11432, United States
  • Eastside Comprehensive Medical Center
    New York, New York 10128, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Neuro-Behavioral Clinical Research, Inc
    North Canton, Ohio 44720, United States
  • IPS Research
    Oklahoma City, Oklahoma 73106, United States
  • Clinical Neuroscience Solutions, Inc - Memphis, TN
    Memphis, Tennessee 38119, United States
  • Research Strategies of Memphis, LLC
    Memphis, Tennessee 38119, United States
  • Donald J. Garcia, Jr., MD, PA
    Austin, Texas 78737, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — This is a phase 2 dose finding proof of concept study therefore data will not be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jul 2019, 13 months.

Results were first posted in Aug 2022, 3 years after primary completion. A results delay was requested in Jul 2020.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 13 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2018
First posted
Jul 13, 2018
StartActual
Jun 13, 2018
Primary completionActual
Jul 22, 2019
CompletionActual
Aug 21, 2019
Results delay requested
Jul 22, 2020
Results first posted
Aug 2, 2022
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03586427
Lead sponsor
Syndeio Biosciences, Inc
Responsible party
Sponsor
First posted
Jul 13, 2018
Start date
Jun 13, 2018
Primary completion
Jul 22, 2019
Completion
Aug 21, 2019
Results posted
Aug 2, 2022
Last update
Apr 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zelquistinel

Start the discussion